… In the case of cilostazol, an antithrombotic agent, the only crystalline form reported … cilostazol
and potentially improve its bioavailability, an investigation into potential polymorphic forms …

… cilostazol is limited owing to its poor aqueous solubility and oral bioavailability. Our aim was
to produce cilostazol … size distribution and stable polymorphic form to increase its dissolution …

… powder, thus the crystalline form of a compound is always less soluble than the corresponding
amorphous form (Ansel et al., 1999). Furthermore, when the ratio of cilostazol:TPGS was …

… cooling of cilostazol is believed to result in polymorphic transition… It may possibly reflect
polymorphic transition of the drug in … Polymorphism has been reported for cilostazol upon thermal …

… for the stable crystalline form of CLT is 159 CCitation40, while the amorphous form had no
… was evidence that there might be a crystalline transition during the drug loading procedure. …

… of cilostazol by crystal engineering, using habit modification method and compare with
micronized cilostazol … polymorphic forms, of which form A is the most stable form. The other two …

… reported cases of cilostazol polymorphism after melting and coolingCitation 40 , the sintering
temperature used in this study was not high enough to alter its crystalline form. The FTIR …

… Therefore, we are now investigating the effect of each of the CLZ polymorphic forms (Form
AC) in the CLZ/Rnano tablet on stability in re-dispersion, drug absorption, and treatment of …

… B, which may spontaneously convert overtime back to form A … incorporation of the hydrophobic
drug - cilostazol (CIL) into the … Our study demonstrates no change in CIL polymorphic form …

… For this investigation, cilostazol (CIL) was selected as model drug, which was classified as a
… 6 and 7) all proved that the sample of CIL received was crystalline and polymorphic form A (…